Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502417 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
A Phase 1 study, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07502417 is a Phase 1 study that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 15 participants.
The verdict
NCT07502417, a Phase 1 study, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
Interventions
- DRUG ABBV-722
- DRUG Ethinyl Estradiol + Levonorgestrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502417
The ClinicalTrials.gov registry entry for NCT07502417 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-722 is the first listed.
NCT07502417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502417 about?
NCT07502417 is a clinical study titled "A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants". The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
What is the current status of trial NCT07502417?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-03-27. Estimated completion is 2026-07.
What interventions are being tested in trial NCT07502417?
The interventions under investigation include: ABBV-722 (DRUG), Ethinyl Estradiol + Levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT07502417?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.